Pediatric ID

Adult ID

Transplant ID

Trainee

Symposium

91 - Non-Antibiotic Approaches to Treating Transplant-Associated Infections

Learning Objectives:

At the conclusion of this session, participants will be able to:

• review the safety and effectiveness of using bacteriophage therapy for multidrug-resistant bacterial infections in transplant recipients
• evaluate the feasibility of integrating virus-specific T-cell therapy into the day-to-day management of transplant patients
• discuss issues surrounding using fecal microbiota transplantation in the transplant population

Presentations:

• 3:15 PM - 3:40 PM

  873 - What is the Rage with Bacteriophage (Therapy)?
  Saima Aslam, MD, MS – University of California, San Diego
• 3:40 PM - 4:05 PM

  874 - Virus-Specific T-cell Therapy in Transplantation: Adopting into Clinical Practice
  Rajiv Khanna, PhD, FAHMS – QIMR Berghofer Medical Research Institute
• 4:05 PM - 4:30 PM

  875 - Transplanting Fecal Microbiota: Friend or Foe?
  Andrew Y. Koh, MD – University of Texas Southwestern

Moderator(s)

• 

  Pearlie Chong, MD, MSCR

  Assistant Professor of Medicine
  University of Texas Southwestern
  Dallas, Texas

  Disclosure: Nothing to disclose
• 

  Rachel Miller, MD

  Professor of Medicine
  Duke University
  Durham, NC

  Disclosure: Synexis: Research Grant

Speaker(s)

• 

  Saima Aslam, MD, MS

  Associate Professor
  University of California, San Diego
  San Diego, CA

  Disclosure: Merck: Consultant
• 

  Rajiv Khanna, PhD, FAHMS

  Senior Scientist
  QIMR Berghofer Medical Research Institute
  Herston, Australia

  Disclosure: Atara Biotherapeutics: Advisory Board, Consultant, Grant/Research Support, Shareholder
  Cellestis: Consultant
  CSL Ltd: Consultant
• 

  Andrew Koh, MD

  Associate Professor
  University of Texas Southwestern
  Dallas, TX

  Disclosure: Merck, Sharpe, and Dohme: Consultant
  Novartis: Research Grant